Telomir Pharmaceuticals, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
68.8M
on 2026-06-30, from 29.6M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
$150.0M
S-3 of 2025-02-14. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$100.0M
Rodman & Renshaw, agreement of 2025-02-14. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
1 quarters
$754K on 2025-06-30 ÷ $792K a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2024-12-09 | Private placement | not read | $7.00 | not stated | 8-K ↗ |